Tobramycin clearance in a cystic fibrosis patient on haemodialysis: implications for dosing

• At: Glasgow (Scotland) (2018)
• Type: Poster
• Poster code: POS-PAA-001
• By: BROWN, Catherine (Alfred Health, Pharmacy)
• Co-author(s): Catherine Elizabeth Brown: Pharmacy, Alfred Health, Melbourne, Australia
  Vanessa Inserra: Pharmacy, Alfred Health, Melbourne, Australia
  Scott Wilson: Renal Medicine, Alfred Health, Melbourne, Australia
  
• Abstract:

  Background

  In the era of conventional high-flux haemodialysis (HF-HD), standardised dosing practices for tobramycin (or any aminoglycoside) are not established for the dialysis dependent patient

  Methods

  Following a 120mg intravenous dose of tobramycin 5 days prior, a 54 year old male with cystic fibrosis and end-stage renal disease recorded a plasma
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login